BMY vs. ISRG: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BMY and ISRG, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BMY | ISRG |
|---|---|---|
| Company Name | Bristol-Myers Squibb Company | Intuitive Surgical, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Health Care Equipment & Supplies |
| Market Capitalization | 97.40 billion USD | 172.91 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | June 1, 1972 | June 16, 2000 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BMY and ISRG by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BMY | ISRG |
|---|---|---|
| 5-Day Price Return | 5.49% | 2.67% |
| 13-Week Price Return | -0.68% | -14.09% |
| 26-Week Price Return | -16.67% | -18.04% |
| 52-Week Price Return | 1.68% | 3.61% |
| Month-to-Date Return | 10.48% | 0.26% |
| Year-to-Date Return | -15.40% | -7.59% |
| 10-Day Avg. Volume | 15.20M | 2.08M |
| 3-Month Avg. Volume | 14.69M | 1.96M |
| 3-Month Volatility | 30.84% | 23.29% |
| Beta | 0.35 | 1.63 |
Profitability
Return on Equity (TTM)
BMY
29.57%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
In the upper quartile for the Pharmaceuticals industry, BMY’s Return on Equity of 29.57% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
ISRG
15.55%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
ISRG’s Return on Equity of 15.55% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
BMY
10.59%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
BMY’s Net Profit Margin of 10.59% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
ISRG
28.51%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
ISRG’s Net Profit Margin of 28.51% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
BMY
17.82%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
BMY’s Operating Profit Margin of 17.82% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
ISRG
28.80%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
An Operating Profit Margin of 28.80% places ISRG in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | BMY | ISRG |
|---|---|---|
| Return on Equity (TTM) | 29.57% | 15.55% |
| Return on Assets (TTM) | 5.41% | 13.75% |
| Net Profit Margin (TTM) | 10.59% | 28.51% |
| Operating Profit Margin (TTM) | 17.82% | 28.80% |
| Gross Profit Margin (TTM) | 73.92% | 66.61% |
Financial Strength
Current Ratio (MRQ)
BMY
1.21
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
BMY’s Current Ratio of 1.21 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
ISRG
5.64
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
ISRG’s Current Ratio of 5.64 is exceptionally high, placing it well outside the typical range for the Health Care Equipment & Supplies industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio (MRQ)
BMY
2.82
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.82, BMY operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
ISRG
0.00
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
Falling into the lower quartile for the Health Care Equipment & Supplies industry, ISRG’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
BMY
-4.77
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
BMY has a negative Interest Coverage Ratio of -4.77. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
ISRG
--
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
Interest Coverage Ratio data for ISRG is currently unavailable.
Financial Strength at a Glance
| Symbol | BMY | ISRG |
|---|---|---|
| Current Ratio (MRQ) | 1.21 | 5.64 |
| Quick Ratio (MRQ) | 1.11 | 4.89 |
| Debt-to-Equity Ratio (MRQ) | 2.82 | 0.00 |
| Interest Coverage Ratio (TTM) | -4.77 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BMY
5.14%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 5.14%, BMY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
ISRG
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
ISRG currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BMY
98.10%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
BMY’s Dividend Payout Ratio of 98.10% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
ISRG
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
ISRG has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BMY | ISRG |
|---|---|---|
| Dividend Yield (TTM) | 5.14% | 0.00% |
| Dividend Payout Ratio (TTM) | 98.10% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BMY
19.09
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
BMY’s P/E Ratio of 19.09 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ISRG
65.69
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
A P/E Ratio of 65.69 places ISRG in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Price-to-Sales Ratio (TTM)
BMY
2.02
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
BMY’s P/S Ratio of 2.02 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
ISRG
18.73
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
With a P/S Ratio of 18.73, ISRG trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
BMY
5.40
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
BMY’s P/B Ratio of 5.40 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
ISRG
10.85
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
ISRG’s P/B Ratio of 10.85 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | BMY | ISRG |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 19.09 | 65.69 |
| Price-to-Sales Ratio (TTM) | 2.02 | 18.73 |
| Price-to-Book Ratio (MRQ) | 5.40 | 10.85 |
| Price-to-Free Cash Flow Ratio (TTM) | 6.61 | 85.88 |